IFNB1 and myeloid sarcoma: The evaluation of lymphocyte counts in patients with MS stratified based on the different therapies showed that patients taking fingolimod or cladribine had significant lower levels of lymphocytes compared to patients taking ocrelizumab or IFN-β (Supplementary Figure 1B).